ЭКЛ Чарльз (GB),МУДАН Сатвиндер (GB),ГРАНДЖ Джон (GB)
申请号：
RU2014121335
公开号：
RU2014121335A
申请日:
2012.12.03
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. The immunomodulator for use in the treatment and / or monitoring a neoplastic tumor disease in a patient, which is to immunogenic therapy due to cell death, simultaneously, separately or sequentially with the administration immunomodulyatora.2. The immunomodulator as claimed in claim. 1, characterized in that said therapy due immunogenic cell death is selected from microwave irradiation directed radiotherapy, embolization, cryotherapy, ultrasound, high-intensity focused ultrasound cyberknife, hyperthermia, radiofrequency destruction, cryoablation, heating electrocautery, introduction of hot water , the introduction of alcohol, embolization, radioactive radiation, photodynamic therapy, laser beam irradiation, and combinations of these types of therapy.3. The immunomodulator as claimed in claim. 1, characterized in that the tumor is metastaticheskoy.4. The immunomodulator as claimed in any one of claims. 1-3, wherein said immunomodulator comprises Mycobacterium.5 whole cells. The immunomodulator as claimed in claim. 4, wherein the Mycobacterium is a non-pathogenic killed by heating Mycobacterium.6. The immunomodulator as claimed in claim. 5, characterized in that the non-pathogenic heat-killed Mycobacterium selected from the M. vaccae, M. obuense, M. parafortuitum, M. aurum, M. w and kombinatsiy.7. The immunomodulator as claimed in claim. 5, characterized in that the non-pathogenic killed Mycobacterium preferably by heating a gritty variant.8. The immunomodulator as claimed in any one of claims. 5-7, characterized in that the non-pathogenic heat-killed Mycobacterium intended for administration by the parenteral, oral, sublingual, nasal or pulmonary putem.9. Immunomodulator according to claim. 8, characterized in that the parenteral Put1. Иммуномодулятор для применения в лечении и/или контроле опухоли неопластического заболевания у пациента, которому предстоит терапия за счет иммуногенной гибели клеток, одновременно, отдельно от или последовательно с введением иммун
